Ligand Pharma (LGND) Offers Highlights from Today's Analyst Day Event
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ligand Provides Highlights from Today’s Analyst Day Event
November 14, 2017 5:25 PM ESTWebcast available at www.ligand.com
SAN DIEGO--(BUSINESS WIRE)-- At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered assets and its OmniAb® and Captisol® technology platforms. Management also discussed its Glucagon Receptor Antagonist internal development program, provided 2017 financial guidance details, and reviewed a preliminary framework for 2018... More
